Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination
| Errataetall: |
CommentOn: J Infect. 2021 Sep;83(3):381-412. - PMID 34161817 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
The Journal of infection - 84(2022), 1 vom: 01. Jan., Seite 94-118 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Favresse, Julien [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 12.01.2022 Date Revised 12.01.2022 published: Print-Electronic CommentOn: J Infect. 2021 Sep;83(3):381-412. - PMID 34161817 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2021.07.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327791969 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327791969 | ||
| 003 | DE-627 | ||
| 005 | 20231225201552.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2021.07.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327791969 | ||
| 035 | |a (NLM)34233149 | ||
| 035 | |a (PII)S0163-4453(21)00327-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Favresse, Julien |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Importance of sample dilution in the evaluation of the antibody response after SARS-CoV-2 vaccination |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2022 | ||
| 500 | |a Date Revised 12.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: J Infect. 2021 Sep;83(3):381-412. - PMID 34161817 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Dilution | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccination | |
| 650 | 4 | |a mRNA vaccine | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 84(2022), 1 vom: 01. Jan., Seite 94-118 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:94-118 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2021.07.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2022 |e 1 |b 01 |c 01 |h 94-118 | ||